Jacob Van Naarden - 01 Feb 2025 Form 4 Insider Report for ELI LILLY & Co (LLY)

Role: EVP & Pres., Lilly Oncology
Signature: /s/ Jonathan Groff for Jacob Van Naarden, pursuant to authorization on file
Issuer symbol: LLY
Transactions as of: 01 Feb 2025
Net transactions value: -$1,143,492
Form type: 4
Filing time: 04 Feb 2025, 16:26:23 UTC
Previous filing: 01 Nov 2024
Next filing: 12 Feb 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LLY	Common Stock	Options Exercise	$0	+3,023	+26%	$0.000000	14,868	01 Feb 2025	Direct
transaction	LLY	Common Stock	Tax liability	$1,143,492	-1,410	-9.5%	$811.08	13,458	01 Feb 2025	Direct
holding	LLY	Common Stock						4,342	01 Feb 2025	Van Naarden Family Trust	F1
holding	LLY	Common Stock						4,302	01 Feb 2025	By spouse	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LLY	Restricted Stock Unit	Options Exercise	$0	-3,023	-100%	$0.000000	0	01 Feb 2025	Common Stock	3,023		Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F2	Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.